Epcoritamab Monotherapy Achieves 67% ORR in Elderly DLBCL, Genmab Reports
GMAB sits 24% above its 52-week low of $20.225.
Summary
Genmab reported strong clinical trial results for its drug epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Monotherapy achieved a 67% overall response rate (ORR) and 58% complete response (CR), while a combination regimen showed a 93% ORR and 86% CR. These high response rates are particularly significant for a patient population with limited treatment options and high unmet medical need. The data was presented at a major medical conference and published in The Lancet Haematology, underscoring its importance for Genmab's pipeline.
At the time of this announcement, GMAB was trading at $25.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.9B. The 52-week trading range was $20.23 to $35.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.